Incyte Corp. (INCY)
115.30
-1.84
(-1.57%)
USD |
NASDAQ |
Oct 02, 16:00
115.30
0.00 (0.00%)
After-Hours: 20:00
Incyte Enterprise Value : 18.68B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 18.68B |
| October 01, 2026 | 19.05B |
| September 30, 2026 | 19.89B |
| September 29, 2026 | 20.26B |
| September 28, 2026 | 20.59B |
| September 25, 2026 | 20.40B |
| September 24, 2026 | 20.51B |
| September 23, 2026 | 20.55B |
| September 22, 2026 | 21.01B |
| September 21, 2026 | 20.55B |
| September 18, 2026 | 20.69B |
| September 17, 2026 | 21.15B |
| September 16, 2026 | 20.57B |
| September 15, 2026 | 19.97B |
| September 14, 2026 | 20.06B |
| September 11, 2026 | 19.92B |
| September 10, 2026 | 20.28B |
| September 09, 2026 | 20.83B |
| September 08, 2026 | 20.50B |
| September 04, 2026 | 20.98B |
| September 03, 2026 | 21.23B |
| September 02, 2026 | 21.39B |
| September 01, 2026 | 20.63B |
| August 31, 2026 | 20.27B |
| August 28, 2026 | 20.50B |
| Date | Value |
|---|---|
| August 27, 2026 | 21.18B |
| August 26, 2026 | 21.25B |
| August 25, 2026 | 21.57B |
| August 24, 2026 | 21.22B |
| August 21, 2026 | 21.19B |
| August 20, 2026 | 21.07B |
| August 19, 2026 | 21.32B |
| August 18, 2026 | 20.32B |
| August 17, 2026 | 20.32B |
| August 14, 2026 | 19.65B |
| August 13, 2026 | 19.72B |
| August 12, 2026 | 19.77B |
| August 11, 2026 | 19.83B |
| August 10, 2026 | 19.93B |
| August 07, 2026 | 19.73B |
| August 06, 2026 | 19.29B |
| August 05, 2026 | 19.58B |
| August 04, 2026 | 19.74B |
| August 03, 2026 | 19.30B |
| July 31, 2026 | 19.52B |
| July 30, 2026 | 20.22B |
| July 29, 2026 | 21.05B |
| July 28, 2026 | 21.62B |
| July 27, 2026 | 19.39B |
| July 24, 2026 | 19.15B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 70.72B |
| Mirum Pharmaceuticals, Inc. | 5.695B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| AbbVie, Inc. | 528.72B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 585.60M |
| Revenue (Quarterly) | 1.674B |
| Total Expenses (Quarterly) | 1.088B |
| EPS Diluted (Quarterly) | 2.812 |
| Gross Profit Margin (Quarterly) | 92.57% |
| Profit Margin (Quarterly) | 34.98% |
| Earnings Yield | 6.81% |
| Operating Earnings Yield | 7.77% |
| Normalized Earnings Yield | 6.912 |